Authors
Latest:
Passed by House, 21st Century Cures Act Could Spur Advances, Weaken FDAViewed by some as a boon for precision medicine, an Alzheimer’s cure, brain research, and opioid abuse prevention, but also seen as weakening the FDA’s regulatory power, the $6.3 billion 21st Century Cures Act passed overwhelmingly in the House Wednesday by a vote of 392-26.
Latest:
Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLCTony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.
Latest:
Dr. Philip Spotlights Ongoing Research Efforts in CRCTony Philip, MD, discusses research efforts underway in colorectal cancer.
Latest:
Dr. Mok on the Results of the U31402-A-U102 Trial in NSCLCTony SK Mok, MD, discusses the rationale for the phase 1 U31402-A-U102 trial in metastatic or unresectable non–small cell lung cancer.
Latest:
Dr. Mok Previews Discussion Topics for the Upcoming COVID-19 WebinarTony S. K. Mok, MD, BMSc, FRCPC, FASCO, previews discussion topics for the upcoming webinar hosted by OncLive on the novel coronavirus 2019 (COVID-19).
Latest:
Dr. Nielsen Discusses the PAM50 AssayTorsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.
Latest:
Dr. Iwase on Elevated Neutrophil to Lymphocyte Ratio to Predict Survival Outcome in TNBCToshiaki Iwase, MD, Department of General Surgery, Chiba Graduate School of Medicine, Chiba, Japan, discusses a study that examined elevated neutrophil to lymphocyte ratio to predict survival outcomes after recurrence in patients with triple-negative breast cancer.
Latest:
Dr. Evans on Challenges of Immunotherapy in Lung CancerTracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.
Latest:
Dr. Tracey Evans on Chemotherapy for the Elderly PatientTracey Evans, MD, Associate Professor of Clinical Medicine University of Pennsylvania Health System, discusses how to determine which patients will benefit from chemotherapy.
Latest:
Discussing Palliative Care Plans Earlier Improves Quality of LifeA team of researchers take a retrospective look at the patterns of how, when, and to whom palliative options are presented to patients with metastatic breast cancer, as an approach for gaining insight on how to improve care for patients with late-stage, terminal cancers.
Latest:
Dr. Liebman on the Use of Digital Surveillance in MelanomaTracey Liebman, MD, discusses the use of digital surveillance in melanoma.
Latest:
Blackwell Explores Emerging Trends in Treating HER2 Metastatic Breast CancerSince its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.
Latest:
Payer Management of Oncology Gets SeriousHealth plans continue to seek methods to curtail cancer costs.
Latest:
Enhanced Recovery Program Improves Outcomes After Colorectal Cancer SurgeryThe adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.
Latest:
Payers Try to Drive Down Costs in Cancer CareSteadily rising expenses and a proliferation of new drugs are speeding adoption of a host of measures designed to contain drug and treatment outlays more directly
Latest:
Dr. Knudsen Discusses the Rationale of the DALIAH Trial in MPNsTrine Alma Knudsen, MD, PhD student, Department of Haematology, Zealand University Hospital, Roskilde, Denmark, discusses the rationale of the DALIAH trial in patients with myeloproliferative neoplasms.
Latest:
Dr. Nguyen on Treatment Approaches for Patients With Advanced Ovarian CancerTrung Nguyen, DO, MBA, clinical assistant professor, Obstetrics and Gynecology, Gynecologic Oncology, Stanford Medicine, discusses treatment approaches for patients with advanced ovarian cancer.
Latest:
T.S. Wiley on Bio-identical Hormone Replacement Therapy for Patients With Breast CancerT.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.
Latest:
Dr. Shore on Stem Cell Transplant in Ethnic PopulationsTsiporah B. Shore, MD, associate director of the Blood and Bone Marrow Transplant Program of Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses stem cell transplantation in patients with hematologic malignancies and are of ethnic populations.
Latest:
Dr Phillips on the Evolution of MDS TreatmentTycel Phillips, MD, discusses the evolution of treatment for patients with myelodysplastic syndromes, highlighting the future of this treatment paradigm.
Latest:
Dr. Phillips on the Current Role of Ibrutinib in MCLTycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.
Latest:
Sleckman to lead O'Neal Comprehensive Cancer CenterBarry Paul Sleckman, MD, PhD, has been named director of the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.
Latest:
Dr. Banerji on the Clinical Activity of VS-6766/Defactinib in KRAS-Mutant TumorsUdai Banerji, MD, discusses the results from a phase 1 trial with the combination of VS-6766 (CH5126766) and defactinib in KRAS-mutant tumors.
